



Pharmacy Quality Assurance Commission  
PO Box 47852 Olympia, WA 98504  
www.doh.wa.gov · TDD Relay: 711

To request this document in another format, call 1-800-525-0127. Deaf or hard of hearing customers, please call 711 (Washington Relay) or email [doh.information@doh.wa.gov](mailto:doh.information@doh.wa.gov).

## January 30, 2026 Weekly Legislative Review Agenda

Time: 12:00 p.m. – 1:00 p.m.  
Location: Zoom ID: **863 0929 9195**  
<https://us02web.zoom.us/j/86309299195>  
Or One tap mobile :  
+12532050468,,86309299195# US  
+12532158782,,86309299195# US (Tacoma)  
**In Person:** Department of Health  
[111 Israel Rd SE](#), #140 (TC2)  
Tumwater WA 98501  
Contact: Joshua Munroe, Rules and Legislative Consultant, 360.502.5058  
[Joshua.Munroe@doh.wa.gov](mailto:Joshua.Munroe@doh.wa.gov)  
Commission Office: [wspqac@doh.wa.gov](mailto:wspqac@doh.wa.gov)

No registration needed. **All attendees will join the call with their audio connection muted.**

### 12:00 p.m.

1. Call to Order
  - 1.1. Roll Call
2. PQAC Bill Report
3. Public Comment Period

1:00 PM (approximately)  
Meeting Adjourned

[Link to Washington State Legislature Bill Information 2026](#)

Monday, January 12 – First day of session  
 Wednesday, February 4 – Policy committee cutoff **Next cutoff**  
 Monday, February 9 – Fiscal committee cutoff  
 Tuesday, February 17 – House of origin cutoff

Wednesday, February 25 – Policy committee cutoff (opposite house)  
 Monday, March 2 – Fiscal committee cutoff (opposite house)  
 Friday, March 6 – Opposite house cutoff  
 Thursday, March 12 – Sine die: Last day allowed for regular session under state constitution

TVW - <http://www.tvw.org/>

Focus Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
<a href="#">HB 2613</a>	Safety and regulatory requirements for compounded medications	<p>Per this bill, drug compounders would not be able to sell, transfer, or distribute drugs compounded under section 503A of the federal Food, Drug, and Cosmetic Act unless a series of conditions are met. These conditions include, but are not limited to, using bulk drug substances that meeting the standards of the U.S. Pharmacopoeia, ensuring those drug substances are a pharmaceutical grade product, conducting and documenting quality control testing of bulk drug substances, and obtaining proof that the bulk drug substances are manufactured under conditions of satisfactory regulatory compliance and oversight.</p> <p>The commission or a duly authorized third party approved by the commission would be allowed to inspect any person or entity that engages in compounding as well as any domestic suppliers, wholesaler, re-packagers, or other providers of bulk drug substances for compounding. The commission can take enforcement action for a violation of this bill and write rules to implement the bill.</p> <p>The bill also includes a provision that invalidates any section determined to be in conflict with federal requirements that are a prescribed condition to the allocation of federal funds to the state.</p>	<p><b>HB 2613</b>  <i>Sponsor(s):</i> Representatives Thai, Parshley, Duerr, Santos, Ormsby, and Hill</p> <p><i>Introduction (House):</i> 1/21/2026, referred to Committee on Health Care &amp; Wellness.  <i>Public Hearing (Health Care &amp; Wellness):</i> 1/30/2026</p>
<a href="#">SB 5924</a>	Expanding prescriptive	Pharmacists that wish to exercise certain diagnosis and prescriptive authority must enter into a collaborative drug therapy agreement (CDTA) with a licensed physician under current statute. This bill expands the	<p><b>SB 5924</b>  <i>Sponsor(s):</i> Senators Slatter, Short, Chapman, Conway, Hasegawa,</p>

Focus Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
	authority for pharmacists	<p>prescriptive authority for pharmacists licensed and practicing in Washington by amending the “practice of pharmacy.” The definition for “practice of pharmacy” in RCW 18.64.011(32) is amended to include “diagnosing and the prescribing or ordering of drugs and devices based on his or her education, training, and experience” as permitted under a pharmacist’s scope of practice.</p> <p>RCW 69.41.030 is also amended to remove a qualifying statement for pharmacists that references a CDTA being a necessary condition for a pharmacist to issue an order or prescription for a legend drug.</p>	<p>Nobles, Orwall, Riccelli, Saldaña, and Shewmake</p> <p><i>Pre-file (Senate): 12/22/2025</i>  <i>Introduction (Senate): 1/12/2026,</i>  referred to Committee on Health &amp; Long-Term Care.  <i>Public Hearing (Health &amp; Long-Term Care): 1/30/2026</i></p>
<a href="#">HB 2302</a>	Expanding prescriptive authority for pharmacists	Companion bill to SB 5924.	<p><b>HB 2302</b></p> <p><i>Sponsor(s):</i> Representatives Thai, Macri, Reed, Zahn, Thomas, Stonier, Ormsby, and Hill</p> <p><i>Pre-file (House): 1/7/2026</i>  <i>Introduction (House): 1/12/2026,</i>  referred to Committee on Health Care &amp; Wellness.</p>
<a href="#">HB 2176</a>	Exempting info in CDTAs from disclosure under the Public Records Act	<p>This bill amends RCW 42.56.360 to exempt collaborative drug therapy agreements (CDTAs) from disclosure under the public records act. Information contained in CDTAs, as well as any attachments or appendices to those CDTAs, are considered confidential and may not be disclosed except under the circumstances outlined in subsection 6(b).</p> <p>Per subsection 6(b), a CDTA or its associated contents may be disclosed if the CDTA is the basis of an order or stipulation finding misconduct resulting in disciplinary action, though personally identifiable information of individuals not facing discipline is still confidential and may not be disclosed. “Personally identifiable information” is defined to include names, mailing addresses, credential numbers, email addresses, practice site facility addresses, and practice site facility phone numbers.</p>	<p><b>HB 2176</b></p> <p><i>Sponsor(s):</i> Representatives Thai, Parshley, Ryu, Reed, Zahn, Gregerson, Reeves, and Fosse</p> <p><i>Introduction (House): 1/12/2026,</i>  referred to Committee on State Government &amp; Tribal Relations.  <i>Public Hearing (State Government &amp; Tribal Relations): 1/14/2026</i>  <i>Executive Session (State Government &amp; Tribal Relations): 1/28/2026</i></p>

Focus Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
<a href="#">HB 2198</a>	Integrating executive order 25-03 to improve regulatory efficiency	<p>This bill establishes new reporting and tracking requirements from state agencies to the governor’s office relating to credentialing information. The stated purpose is to provide better information to applicants. The list of agencies defined under RCW 43.42A.010 is expanded, and those agencies must track and record information relating to credential applications such the time it takes to make credential decisions, number of pending and completed applications, and application and credential fee amounts.</p> <p>Each agency must prepare, maintain, and report credentialing information in the statewide credential catalog and central online repository of credential information. RCW 43.42A.030 is amended to list the required elements for each catalog entry, how entries must be updated, and how the state must ensure website and repository accessibility to applicants. Agency performance relating to tracking credential timelines will be posted on the department’s website starting with the 2027 reporting period, and the bill outlines agency deadlines for compiling and reporting credentialing information. If the agency does not meet its published decision deadline after receiving a completed application, it shall refund the application fee.</p>	<p><b>HB 2198</b>  <i>Sponsor(s):</i> Representatives Richards, Leavitt, Ryu, Dufault, Zahn, Rule, Bronoske, Reeves, and Fosse</p> <p><i>Pre-file (House):</i> 12/26/2025  <i>Introduction (House):</i> 1/12/2026, referred to Committee on State Government &amp; Tribal Relations.  <i>Public Hearing (State Government &amp; Tribal Relations):</i> 1/23/2026</p>
<a href="#">SB 5968</a>	Integrating executive order 25-03 to improve regulatory efficiency	Companion bill to HB 2198.	<p><b>SB 5968</b>  <i>Sponsor(s):</i> Senators Krishnadasan, Liias, and Shewmake</p> <p><i>Introduction (Senate):</i> 1/12/2026, referred to Committee on State Government, Tribal Affairs &amp; Elections.  <i>Public Hearing (State Government, Tribal Affairs &amp; Elections):</i> 1/16/2026  <i>Executive Session (State Government, Tribal Affairs &amp; Elections):</i> 1/23/2026; passed to</p>

Focus Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
			Rules Committee for second reading (1/26).
<a href="#">SB 5921</a>	Psilocybin program	<p>The bill establishes a medical psilocybin program within DOH, and directs DOH to issue licenses to clinicians and producers. Permitted clinicians may write psilocybin authorizations to patients with a “qualifying condition” and explicitly states that determining a qualifying condition is at the sole discretion of the clinician, and all professional liability is borne by the clinician. The bill protects producers, clinicals, and qualified patients from prosecution or penalty for participating in the program but does not protect these entities from liability/prosecution for activities not authorized in the psilocybin act, driving under the influence of psilocybin, or malpractice related to psilocybin treatment. The program excludes synthetic psilocybin.</p> <p>DOH is directed to establish training parameters, treatment and safety protocols, best practices for producers and clinicians, data collection requirements, a registry for psilocybin patients accessible to prescribers, and other requirements to ensure an effective program. The bill also requires the monitoring of producers and clinicians for compliance and rulemaking to outline those compliance requirements, product formulation and preparation standards, and how de-identified patient data may be collected.</p>	<p><b>SB 5921</b>  <i>Sponsor(s):</i> Senators Salomon, Lovelett, Nobles, Riccelli, Saldaña, Shewmake, and Slatter</p> <p><i>Pre-file (Senate):</i> 12/19/2025  <i>Introduction (Senate):</i> 1/12/2026, referred to Committee on Health &amp; Long-Term Care.  <i>Public Hearing (Health &amp; Long-Term Care):</i> 1/27/2026</p>

Agency Request Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
<a href="#">SB 5988</a>	Establishing fee authority for accreditation services provided	SB 5988 allows DOH to apply to the federal Department of Health and Human Services for approval to accredit opioid treatment programs (OTPs). If approved, the department will execute its responsibilities as an	<p><b>SB 5988</b>  <i>Sponsor(s):</i> Senator Robinson; by request of Department of Health</p>

Agency Request Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
	to opioid treatment programs	accrediting body according to HHS policies and procedures and establish OTP accreditation fees in rule.	<i>Pre-file (Senate): 1/5/2026</i> <i>Introduction (Senate): 1/12/2026,</i> <i>referred to Committee on Ways &amp; Means.</i> <i>Public Hearing (Ways &amp; Means):</i> <i>1/19/2026</i>
<a href="#">HB 2437</a>	Establishing fee authority for accreditation services provided to opioid treatment programs	Companion bill to SB 5988.	<b>HB 2437</b> <i>Sponsor(s): Representatives Lekanoff, Parshley, Ryu, Peterson, Simmons, Ramel, Davis, Macri, and Nance; by request of Department of Health</i>  <i>Introduction (House): 1/13/2026,</i> <i>referred to Committee on Health Care &amp; Wellness.</i> <i>Public Hearing (Health Care &amp; Wellness): 1/20/2026</i> <i>Executive Session (Health Care &amp; Wellness): 1/30/2026</i>

Additional Bills to Watch			
Bill # /Companion	Short Title		Committee Action (subject to change)
<a href="#">SHB 2145</a>	Protecting patient access to discounted medications and health care services – 340B drug pricing program	<b>SHB 2145</b>	<i>Sponsor(s): Representatives Thai, Macri, Obras, Parshley, Tharinger, Salahuddin, Stonier, Berry, Zahn, Bergquist, Lekanoff, Fosse, Stearns, Entenman, Duerr, Wylie, Reed, Fey, Hill, Pollet, Santos, Taylor, Hall, Bernbaum, Berg, Ormsby, Reeves, Ryu, Kloba, Ramel, Doglio, Mena, Cortes, Street, Scott, Thomas, Morgan, Gregerson, Goodman, Farivar, and Davis</i>

Additional Bills to Watch		
Bill # /Companion	Short Title	Committee Action (subject to change)
		<p><i>Introduction (House):</i> 1/12/2026, referred to Committee on Health Care &amp; Wellness.</p> <p><i>Public Hearing (Health Care &amp; Wellness):</i> 1/20/2026</p> <p><i>Executive Session (Health Care &amp; Wellness):</i> 1/23/2026; substitute adopted and passed through committee with a DO PASS recommendation. Referred to Appropriations (1/28).</p>
<a href="#">SB 5981</a>	Protecting patient access to discounted medications and health care services – 340B drug pricing program	<p><b><u>SB 5981</u></b></p> <p><i>Sponsor(s):</i> Senators Cleveland, Slatter, Harris, Bateman, Alvarado, Chapman, Dhingra, Frame, Hasegawa, Liias, Nobles, Pedersen, Saldaña, and Valdez</p> <p><i>Introduction (Senate):</i> 1/12/2026, referred to Committee on Health &amp; Long-Term Care.</p> <p><i>Public Hearing (Health &amp; Long-Term Care):</i> 1/16/2026</p> <p><i>Executive Session (Health &amp; Long-Term Care):</i> 1/27/2026; <a href="#">amendment</a> adopted and substitute passed through committee with a DO PASS recommendation.</p>
<a href="#">SHB 2152</a>	Medical use of cannabis by qualifying patients in specified health care facilities	<p><b><u>SHB 2152</u></b></p> <p><i>Sponsor(s):</i> Representatives Kloba, Rude, Parshley, Ryu, Chase, Callan, Jacobsen, Fosse, Doglio, Simmons, Scott, Pederson, Reed, Obras, Fitzgibbon, Cortes, Zahn, Wylie, Morgan, Gregerson, Reeves, Farivar, Hill, and Donaghy</p> <p><i>Introduction (House):</i> 1/12/2026, referred to Committee on Health Care &amp; Wellness.</p> <p><i>Public Hearing (Health Care &amp; Wellness):</i> 1/13/2026</p> <p><i>Executive Session (Health Care &amp; Wellness):</i> 1/21/2026, substitute adopted and passed through committee with a DO PASS recommendation; referred to Rules 2 Review (1/26).</p>
<a href="#">SB 5900</a>	Medical use of cannabis by qualifying patients in specified health care facilities	<p><b><u>SB 5900</u></b></p> <p><i>Sponsor(s):</i> Senators Riccelli, Robinson, Hasegawa, Nobles, Saldaña, and C. Wilson</p> <p><i>Pre-file (Senate):</i> 12/16/2025</p> <p><i>Introduction (Senate):</i> 1/12/2026, referred to Committee on Health &amp; Long-Term Care.</p>
<a href="#">HB 2157</a>	Regulating high-risk AI system development	<p><b><u>HB 2157</u></b></p> <p><i>Sponsor(s):</i> Representatives Ryu, Stearns, Ramel, Parshley, Reeves, Reed, Santos, Zahn, Street, Duerr, Gregerson, Ormsby, Scott, Shavers, Thai, Macri, Fosse, Pollet, and Donaghy</p>

Additional Bills to Watch		
Bill # /Companion	Short Title	Committee Action (subject to change)
		<p><i>Public Hearing (Technology, Economic Development &amp; Veterans): 1/14/2026</i></p> <p><i>Executive Session (Technology, Economic Development &amp; Veterans): 1/23/2026, no action taken</i></p> <p><i>2<sup>nd</sup> Executive Session (Technology, Economic Development &amp; Veterans): 1/27/2026, executive action taken</i></p>
<a href="#">SB 5951</a>	Expanding access to albuterol in public and private schools	<p><b>SB 5951</b></p> <p><i>Sponsor(s): Senators Cortes, Nobles, Orwall, Slatter, Stanford, and C. Wilson</i></p> <p><i>Introduction (Senate): 1/12/2026, referred to Committee on Early Learning &amp; K-12 Education</i></p> <p><i>Public Hearing (Early Learning &amp; K-12 Education): 1/21/2026</i></p> <p><i>Executive Session (Early Learning &amp; K-12 Education): 1/29/2026</i></p>
<a href="#">HB 2360</a>	Expanding access to albuterol in public and private schools	<p><b>HB 2360</b></p> <p><i>Sponsor(s): Representatives Donaghy, Reed, Engell, Bronoske, Zahn, Thomas, Ormsby, Fosse, Salahuddin, Hill, and Pollet</i></p> <p><i>Pre-file (House): 1/9/2026</i></p> <p><i>Introduction (House): 1/12/2026, referred to Committee on Education</i></p> <p><i>Public Hearing (Education): 1/19/2026</i></p>
<a href="#">HB 2242</a>	Preserving access to preventative services by clarifying state authority and definitions	<p><b>HB 2242</b></p> <p><i>Sponsor(s): Representatives Bronoske, Doglio, Parshley, Simmons, Berry, Ramel, Thomas, Ormsby, Thai, Macri, Fosse, Pollet, Obras, Wylie, and Zahn; by request of Governor Ferguson and the Insurance Commissioner</i></p> <p><i>Public Hearing (Health Care &amp; Wellness): 1/16/2026</i></p> <p><i>Executive Session (Health Care &amp; Wellness): 1/23/2026, no action taken</i></p> <p><i>2<sup>nd</sup> Executive Session (Health Care &amp; Wellness): 1/28/2026</i></p>
<a href="#">SB 5967</a>	Preserving access to preventative services by clarifying state authority and definitions	<p><b>SB 5967</b></p> <p><i>Sponsor(s): Senators Cleveland, Harris, Hasegawa, Lias, and Pedersen; by request of Governor Ferguson and the Insurance Commissioner</i></p> <p><i>Introduction (Senate): 1/12/2026, referred to Committee on Health &amp; Long-Term Care</i></p> <p><i>Public Hearing (Health &amp; Long-Term Care): 1/15/2026</i></p>

Additional Bills to Watch		
Bill # /Companion	Short Title	Committee Action (subject to change)
		<i>Executive Session (Health &amp; Long-Term Care): 1/20/2026, passed through committee by majority vote; passed to Rules Committee for second reading (1/22).</i>
<a href="#">SHB 2247</a>	Veterinarian-client-patient relationships	<p><b><u>SHB 2247</u></b>  <i>Sponsor(s):</i> Representatives Parshley, Lekanoff, Reed, Leavitt, Zahn, Gregerson, Berg, and Fosse</p> <p><i>Introduction (House): 1/12/2026, referred to Committee on Health Care &amp; Wellness</i>  <i>Public Hearing (Health Care &amp; Wellness): 1/14/2026</i>  <i>Executive Session (Health Care &amp; Wellness): 1/23/2026, substitute adopted and passed through committee with a DO PASS recommendation. Referred to Rules 2 Review (1/27).</i></p>
<a href="#">SB 6072</a>	Veterinarian-client-patient relationships	<p><b><u>SB 6072</u></b>  <i>Sponsor(s):</i> Senators Cleveland, Warnick, and Nobles</p> <p><i>Introduction (Senate): 1/13/2026, referred to Committee on Health &amp; Long-Term Care</i>  <i>Public Hearing (Health &amp; Long-Term Care): 1/23/2026</i></p>
<a href="#">HB 2261</a>	Ensuring transparency in credentials and communications between patients and health care professionals	<p><b><u>HB 2261</u></b>  <i>Sponsor(s):</i> Representatives Marshall and Barnard</p> <p><i>Introduction (House): 1/12/2026, referred to Committee on Health Care &amp; Wellness</i>  <i>Public Hearing (Health Care &amp; Wellness): 1/21/2026</i>  <i>Executive Session (Health Care &amp; Wellness): 1/28/2026</i></p>
<a href="#">SB 6166</a>	Ensuring transparency in credentials and communications between patients and health care professionals	<p><b><u>SB 6166</u></b>  <i>Sponsor(s):</i> Senators Muzzall and Chapman</p> <p><i>Introduction (Senate): 1/15/2026, referred to Committee on Health &amp; Long-Term Care</i></p>

Additional Bills to Watch		
Bill # /Companion	Short Title	Committee Action (subject to change)
<a href="#">HB 2291</a>	Kratom consumer protection act	<p><b>HB 2291</b>  <i>Sponsor(s):</i> Representatives Reeves, Stonier, Parshley, Leavitt, Gregerson, Goodman, Fosse, Pollet, and Bernbaum</p> <p><i>Pre-file (House):</i> 1/7/2026  <i>Introduction (House):</i> 1/12/2026, referred to Committee on Consumer Protection &amp; Business  <i>Public Hearing (Consumer Protection &amp; Business):</i> 1/30/2026</p>
<a href="#">HB 2383</a>	Involuntary treatment act	<p><b>HB 2383</b>  <i>Sponsor(s):</i> Representatives Walsh and Graham</p> <p><i>Pre-file (House):</i> 1/9/2026  <i>Introduction (House):</i> 1/12/2026, referred to Committee on Civil Rights &amp; Judiciary</p>
<a href="#">HB 2453</a>	Psychiatric pharmacists in 23-hour crisis relief centers	<p><b>HB 2453</b>  <i>Sponsor(s):</i> Representatives Farivar, Thai, Scott, and Reed</p> <p><i>Introduction (House):</i> 1/13/2026, referred to Committee on Civil Rights &amp; Judiciary  <i>Public Hearing (Civil Rights &amp; Judiciary):</i> 1/27/2026</p>
<a href="#">SB 5452</a>	Licensing board-certified psychiatric pharmacists as agency-affiliated counselors	<p><b>SB 5452</b>  <i>Sponsor(s):</i> Senators Slatter and Nobles</p> <p><i>Re-Introduction (Senate):</i> 1/12/2026, retained in present status (Committee on Health &amp; Long-Term Care)</p>
<a href="#">HB 1124</a>	Establishing a prescribing psychologist certification	<p><b>HB 1124</b>  <i>Sponsor(s):</i> Representatives Simmons, Macri, Senn, Stonier, Ormsby, Tharinger, Kloba, Duerr, Ryu, Morgan, Reed, Callan, Obras, Doglio, Ortiz-Self, Goodman, Reeves, and Hill</p> <p><i>Re-Introduction (House):</i> 1/12/2026, retained in present status (Committee on Health Care &amp; Wellness)</p>

Additional Bills to Watch		
Bill # /Companion	Short Title	Committee Action (subject to change)
<a href="#">SSB 5112</a>	Establishing a prescribing psychologist certification	<b>SSB 5112</b> <i>Sponsor(s)</i> : Senators Bateman, Harris, Shewmake, Trudeau, Conway, Nobles, Riccelli, C. Wilson, Robinson, and Hasegawa  <i>Re-Introduction (Senate)</i> : 1/12/2026, retained in present status (Rules Committee)
<a href="#">HB 1888</a>	Naturopathic physician scope-of-practice	<b>HB 1888</b> <i>Sponsor(s)</i> : Representatives Berg, Walen, Wylie, Doglio, Ryu, Parshley, Goodman, Santos, Morgan, Duerr, Ramel, Hill, and Macri  <i>Re-Introduction (House)</i> : 1/12/2026, retained in present status (Committee on Health Care & Wellness)
<a href="#">SB 5765</a>	Psychiatric pharmacists	<b>SB 5765</b> <i>Sponsor(s)</i> : Senators Slatter, Nobles, and Trudeau  <i>Re-Introduction (Senate)</i> : 1/12/2026, retained in present status (Committee on Health Care & Wellness)
<a href="#">HB 1675</a>	Corporate practice of medicine	<b>HB 1675</b> <i>Sponsor(s)</i> : Representatives Thai and Macri  <i>Re-Introduction (House)</i> : 1/12/2026, retained in present status (Committee on Health Care & Wellness)
<a href="#">2SSB 5387</a>	Corporate practice of medicine	<b>SB 5387</b> <i>Sponsor(s)</i> : Senators Robinson, Hasegawa, Lias, Nobles, Riccelli, Stanford, and Valdez  <i>Re-Introduction (Senate)</i> : 1/12/2026, Rules Committee relieved of further consideration. On motion, referred to Ways & Means.
<a href="#">SB 6254</a>	Leveraging AI to streamline regulatory language	<b>SB 6254</b> <i>Sponsor(s)</i> : Senators Braun, Boehnke, Gildon, and Wellman  <i>Introduction (Senate)</i> : 1/21/2026, referred to Committee on State Government, Tribal Affairs & Elections.

Additional Bills to Watch		
Bill # /Companion	Short Title	Committee Action (subject to change)
<a href="#">SB 6287</a>	Preparation, distribution, and sale of kratom products	<p><b>SB 6287</b>  <i>Sponsor(s):</i> Senator Salomon</p> <p><i>Introduction (Senate):</i> 1/22/2026, referred to Committee on Labor &amp; Commerce.  <i>Public Hearing (Labor &amp; Commerce):</i> 1/27/2026</p>
<a href="#">E2SSB 5594</a>	Biosimilar medicines and interchangeable biological products	<p><b>E2SSB 5594</b>  <i>Sponsor(s):</i> Senators Harris, Cleveland, Hasegawa, and Shewmake</p> <p><i>Third Reading (Rules):</i> 1/19/2026, Rules Committee relieved of further consideration.  <i>Floor Vote (Senate):</i> 1/21/2026, <b>floor amendment adopted and bill passed by majority vote (49/0/0).</b>  <i>First Reading (House):</i> 1/26/2026, referred to Committee on Health Care &amp; Wellness.</p>

Dead/dormant Bills (relevant if needed to pass the budget)		
Bill # /Companion	Short Title	Bill Summary